Stanford’s world class team of physicians, fellow and resident trainees, nurses, and research coordinators are actively involved in clinical research that helps improve the care of interstitial lung disease patients. Stanford’s ILD clinic has a robust clinical research program that offers a variety of types of protocols to patients with interstitial lung disease, including observational research, drug treatment clinical trials, and health sciences research that are described below.

The majority of our drug treatment trials are phase II and II and they are all outpatient studies of varying duration.  Our clinical trials are both industry and NIH funded.  When launching a new clinical trial, we typically review our own ILD database for qualified participants, but also recruit from the broader Bay Area and beyond.  Participants do not need to be Stanford patients.  Interested participants or their healthcare provider can email or call Susan Jacobs RN, MS, Research Nurse Manager 650 725 8083 to refer a patient for eligibility evaluation.

You can find out more about each trial or see if you might be a candidate by calling the Clinical Research Coordinator listed with each one.  You can also review these trials by reading about them on Clinicaltrials.gov; each trial has a National Clinical Trial (NCT) identifier which is also listed below.

Observational studies involve observing and collecting data on patients over time. These studies often involve a patient registry in which information on a patient’s symptoms, medications, medical test results, lab or tissue samples, and/or clinical course is collected and securely stored.

All patients with interstitial lung disease (ILD) evaluated at Stanford have the opportunity to participate in the Stanford ILD patient registry. Stanford ILD patients are asked to verbally provide informed consent; participation in the Stanford ILD registry is voluntary. Stanford’s team has used data from this registry to understand the natural history and prognosis of patients with ILD and to gain insights into interventions that may help improve the care of patients with ILD. The Stanford ILD patient registry has also been used to facilitate collaborative projects with colleagues from other divisions, such as rheumatology and radiology, and other institutions.

Stanford ILD Patient Registry
PI: Rishi Raj MD
CRC: Susan Jacobs 
Status: Enrollment is open to Stanford ILD clinic patients
NCT#: NA

Pulmonary Fibrosis Foundation Patient Registry
PI: Rishi Raj MD
CRC: Jannet Estrada, BA, CRCA
Status:  Enrollment is closed for this observational patient registry, but study is active
NCT#: 01915511

Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF-PRO; ILD-PRO)
PI: Rishi Raj MD
CRC: Jannet Estrada, BA,CRCA
Status: Enrollment in this observational patient registry is currently open to enrollment; newly enrolled participants are followed with previously enrolled participants with IPF.
NCT#: 01915511

Health services research involves studying how patients access health care, and understanding the costs and outcomes associated with their health care. At Stanford, our physician scientists have used Centers for Medicare and Medicaid Services (CMS) data, the National Inpatient Sample (NIS) data, and other large databases to study health care access, healthcare disparities, healthcare outcomes, and economic costs in interstitial lung disease. For example, Stanford’s team has evaluated the patterns of health care testing prior to ILD diagnosis in Medicare patients to understand potential delays to diagnosis and have evaluated hospitalized patients with ILD who receive mechanical ventilation to understand their outcomes. Collaborative work with colleagues from Stanford’s Center for Health Policy, Center for Primary Care and Outcomes Research, and Center for Population Health Sciences helps enable projects like these.